α3β1 integrin/JNK signaling inhibits the uptake and accumulation of gemcitabine in pancreatic cancer cells by ultimately inhibiting the expression of the ENT1, although the detailed molecular mechanisms remain unclear [62]. Here, SLC29A1 is linked to pancreatic neoplasm.